Jens Pfannkuche
Amministratore Delegato presso GILUPI GmbH
Profilo
Jens Pfannkuche is currently the Managing Director at GILUPI GmbH since 2016.
Prior to this, he worked as the Head of Business Development at B·R·A·H·M·S GmbH from 2007 to 2012.
Posizioni attive di Jens Pfannkuche
| Società | Posizione | Inizio |
|---|---|---|
GILUPI GmbH
 GILUPI GmbH Medical SpecialtiesHealth Technology GILUPI GmbH develops and produces products for the in-vivo isolation of rare cells from the circulation. Its product GILUPI CellCollector enables the detection of rare cells directly from the blood of patients. The company was founded by Klaus Lücke, Ulrich Pison, Michael Giersig, and Fabian Rüchardt in 2006 and is headquartered in Potsdam, Germany. | Amministratore Delegato | 01/07/2016 |
Precedenti posizioni note di Jens Pfannkuche
| Società | Posizione | Fine |
|---|---|---|
B·R·A·H·M·S GmbH
 B·R·A·H·M·S GmbH Miscellaneous Commercial ServicesCommercial Services B·R·A·H·M·S GmbH engages in the development and manufacture of novel diagnostic testing procedures. Its products include B·R·A·H·M·S PCT (Procalcitonin), MR-proADM (Mid-regional proadrenomedullin), Copeptin proAVP, Neopterin, and KRYPTOR Instruments. The company was founded in 1994 and is headquartered in Hennigsdorf, Germany. | Corporate Officer/Principal | 01/05/2012 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
B·R·A·H·M·S GmbH
B·R·A·H·M·S GmbH Miscellaneous Commercial ServicesCommercial Services B·R·A·H·M·S GmbH engages in the development and manufacture of novel diagnostic testing procedures. Its products include B·R·A·H·M·S PCT (Procalcitonin), MR-proADM (Mid-regional proadrenomedullin), Copeptin proAVP, Neopterin, and KRYPTOR Instruments. The company was founded in 1994 and is headquartered in Hennigsdorf, Germany. | Commercial Services |
GILUPI GmbH
GILUPI GmbH Medical SpecialtiesHealth Technology GILUPI GmbH develops and produces products for the in-vivo isolation of rare cells from the circulation. Its product GILUPI CellCollector enables the detection of rare cells directly from the blood of patients. The company was founded by Klaus Lücke, Ulrich Pison, Michael Giersig, and Fabian Rüchardt in 2006 and is headquartered in Potsdam, Germany. | Health Technology |
- Borsa valori
- Insiders
- Jens Pfannkuche
